LAS VEGAS – The latest topical treatments “are going to change the way we treat onychomycosis,” Dr. David Pariser said at the Skin Disease Education Foundation’s annual Las Vegas dermatology...
LAS VEGAS – The latest topical therapies for onychomycosis are strong enough to penetrate nail polish, but patients report few side effects.
“New topical antifungals have improved the challenge of...
NEWPORT BEACH, CALIF. – There is a role for topical cidofovir in the treatment of recalcitrant warts in children, Dr. James R. Treat said at Skin Disease Education Foundation’s Women’s &...
NEWPORT BEACH, CALIF.– Patients with discoid lupus should be checked routinely for systemic disease, but complete autoantibody studies aren’t necessary for those patients with a prior work-up and a...
VIENNA – Patients treated with an anti–tumor necrosis factor drug had a 5% annual rate of developing one or more psoriasiform skin lesions in a review of more than 400 patients who received these...
SONOMA, CALIF.– Data support dosage escalation or intensification for patients who don’t respond to biologic therapy for psoriasis, but only for three of the four biologic agents available in the...
SILVER SPRING, MD. – The human monoclonal antibody secukinumab is expected to be the first biologic that targets interleukin-17A to be approved by the agency for treating psoriasis, with a Food and...
AMSTERDAM – The investigational biologic agent secukinumab continued to show strong efficacy through 52 weeks of treatment in a new secondary analysis of the pivotal phase III ERASURE trial.
For...
AMSTERDAM – Does pushing for a PASI 90 response instead of settling for a PASI 75 matter to patients being treated for moderate-to-severe chronic plaque psoriasis?
You bet it does, Dr. Mark G....
ORLANDO – As dermatologists do their routine skin checks, they also should pay attention to the breast and the nipple, Dr. David T. Harvey advised in a presentation at the annual meeting of the...